FDA Expands Test for Gastric and Esophageal Cancers - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

  • By

  • Kathryn Wighton

  • July 14, 2026

  • 2 min

Share

  • 1

    The FDA approved Agilent Technologies' companion diagnostic for identifying tumors expressing PD-L1 in gastric and esophageal cancers.

  • 2

    The approval is for patients with esophageal squamous cell carcinoma, gastric tumors, gastroesophageal junction tumors, and esophageal adenocarcinoma.

  • 3

    The PD-L1 IHC 28-8 pharmDx assay is a diagnostic aid for detecting PD-L1 expression with a Combined Positive Score of 1 or greater.

  • 4

    Esophageal cancer is the 11th most common cancer globally, with over 510,000 new cases and 445,000 deaths annually.

  • 5

    Gastric cancer ranks fifth in global incidence, with approximately 968,000 new cases and 660,000 deaths each year.

Original Source(s)

FDA Expands Test for Gastric and Esophageal Cancers

  • by Kathryn Wighton

  • July 14, 2026

Related Content

Triple-positive profile may flag adverse prostate cancer pathology

A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.

Vampire bats may link Chagas cycles

Molecular screening detected Trypanosoma cruzi in 42% of sampled bats in northern Belize, raising questions about their role in parasite transmission.

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.